Similar articles for PMID: 20554729

Year	Number of Results
1983	1
1994	1
1995	1
1996	1
1997	1
2000	2
2001	1
2004	5
2005	3
2006	5
2007	13
2008	11
2009	13
2010	14
2011	19
2012	15
2013	12
2014	13
2015	15
2016	24
2017	15
2018	15
2019	20
2020	17
2021	11
2022	9
2023	4
2024	0

1

Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.

Ahlgren S, Orlova A, Wållberg H, Hansson M, Sandström M, Lewsley R, Wennborg A, Abrahmsén L, Tolmachev V, Feldwisch J. Ahlgren S, et al. J Nucl Med. 2010 Jul;51(7):1131-8. doi: 10.2967/jnumed.109.073346. Epub 2010 Jun 16. J Nucl Med. 2010. PMID: 20554729 Free article.

2

Comparative biodistribution of imaging agents for in vivo molecular profiling of disseminated prostate cancer in mice bearing prostate cancer xenografts: focus on 111In- and 125I-labeled anti-HER2 humanized monoclonal trastuzumab and ABY-025 affibody.

Malmberg J, Sandström M, Wester K, Tolmachev V, Orlova A. Malmberg J, et al. Nucl Med Biol. 2011 Nov;38(8):1093-102. doi: 10.1016/j.nucmedbio.2011.04.005. Epub 2011 Jun 22. Nucl Med Biol. 2011. PMID: 22137850

3

Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.

Orlova A, Jonsson A, Rosik D, Lundqvist H, Lindborg M, Abrahmsen L, Ekblad C, Frejd FY, Tolmachev V. Orlova A, et al. J Nucl Med. 2013 Jun;54(6):961-8. doi: 10.2967/jnumed.112.110700. Epub 2013 Mar 25. J Nucl Med. 2013. PMID: 23528382 Free article.

4

First-in-human molecular imaging of HER2 expression in breast cancer metastases using the 111In-ABY-025 affibody molecule.

Sörensen J, Sandberg D, Sandström M, Wennborg A, Feldwisch J, Tolmachev V, Åström G, Lubberink M, Garske-Román U, Carlsson J, Lindman H. Sörensen J, et al. J Nucl Med. 2014 May;55(5):730-5. doi: 10.2967/jnumed.113.131243. Epub 2014 Mar 24. J Nucl Med. 2014. PMID: 24665085 Free article. Clinical Trial.

5

Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.

Orlova A, Tran T, Widström C, Engfeldt T, Eriksson Karlström A, Tolmachev V. Orlova A, et al. Int J Mol Med. 2007 Sep;20(3):397-404. Int J Mol Med. 2007. PMID: 17671747

6

Influence of an aliphatic linker between DOTA and synthetic Z(HER2:342) Affibody molecule on targeting properties of the (111)In-labeled conjugate.

Tolmachev V, Feldwisch J, Lindborg M, Baastrup B, Sandström M, Orlova A. Tolmachev V, et al. Nucl Med Biol. 2011 Jul;38(5):697-706. doi: 10.1016/j.nucmedbio.2010.11.013. Epub 2011 Mar 3. Nucl Med Biol. 2011. PMID: 21718945

7

On the selection of a tracer for PET imaging of HER2-expressing tumors: direct comparison of a 124I-labeled affibody molecule and trastuzumab in a murine xenograft model.

Orlova A, Wållberg H, Stone-Elander S, Tolmachev V. Orlova A, et al. J Nucl Med. 2009 Mar;50(3):417-25. doi: 10.2967/jnumed.108.057919. Epub 2009 Feb 17. J Nucl Med. 2009. PMID: 19223403 Free article.

8

Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.

Ahlgren S, Wållberg H, Tran TA, Widström C, Hjertman M, Abrahmsén L, Berndorff D, Dinkelborg LM, Cyr JE, Feldwisch J, Orlova A, Tolmachev V. Ahlgren S, et al. J Nucl Med. 2009 May;50(5):781-9. doi: 10.2967/jnumed.108.056929. Epub 2009 Apr 16. J Nucl Med. 2009. PMID: 19372467 Free article.

9

¹¹¹In/⁶⁸Ga-Labeled anti-epidermal growth factor receptor, native chemical ligation cyclized Affibody Z_HER2:342min.

Chopra A. Chopra A. 2013 Apr 3 [updated 2013 May 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. 2013 Apr 3 [updated 2013 May 23]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 23700641 Free Books & Documents. Review.

10

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [68Ga]ABY-025 Affibody PET/CT.

Sörensen J, Velikyan I, Sandberg D, Wennborg A, Feldwisch J, Tolmachev V, Orlova A, Sandström M, Lubberink M, Olofsson H, Carlsson J, Lindman H. Sörensen J, et al. Theranostics. 2016 Jan 1;6(2):262-71. doi: 10.7150/thno.13502. eCollection 2016. Theranostics. 2016. PMID: 26877784 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

215 results

Results by year